Aug 2026· Biomedicines· Vol 14· 0 citations· 28 references
Medicine
TL;DR
Findings support an individualized, risk-adapted sequencing approach in carefully selected patients but do not establish equivalence or justify routine deferral.
Abstract
Background/Objectives: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are commonly used as first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. However, the optimal timing of CDK4/6i initiation remains uncertain. This study compared overall survival (OS) between upfront first-line and deferred second-line CDK4/6i use in routine clinical practice. Methods: This retrospective, two-center cohort study included 403 patients with hormone receptor-positive, HER2-negative metastatic breast cancer who received a CDK4/6i between January 2019 and December 2024. Patients were categorized into upfront-use and deferred-use groups according to whether CDK4/6i treatment was initiated in the first or second metastatic treatment line. Overall survival was estimated using the Kaplan–Meier method. An exploratory analysis of progression-free survival (PFS) from CDK4/6i initiation was also performed. Cox proportional hazards regression, inverse probability of treatment weighting (IPTW), and a 12-month landmark analysis were performed. Results: Of 403 patients, 311 received upfront treatment and 92 received deferred treatment. At a median follow-up of 63.0 months, the deferred-use group had higher rates of visceral metastasis and endocrine-resistant disease. Median PFS from CDK4/6i initiation was longer in the upfront-use group than in the deferred-use group (27.0 vs. 14.0 months; log-rank p < 0.001). Median OS was 61.0 months in the upfront-use group and 76.0 months in the deferred-use group, without a statistically significant difference (log-rank p = 0.059). After adjustment for clinical factors and year of metastatic diagnosis, deferred use was not independently associated with OS (adjusted hazard ratio [HR] 1.167, 95% confidence interval [CI] 0.772–1.765, p = 0.463). Similar results were obtained in the IPTW analysis (HR 0.925, 95% CI 0.552–1.549; p = 0.766) and the 12-month landmark analysis. Conclusions: Deferred second-line CDK4/6i use was not independently associated with inferior overall survival compared with upfront use. These findings support an individualized, risk-adapted sequencing approach in carefully selected patients but do not establish equivalence or justify routine deferral.
It was unable to demonstrate an association between HER2 status and PFS or OS among patients receiving CDK4/6 inhibitor therapy, and the clinical significance of HER2 status in patients treated with CDK4/6 inhibitors remains unclear.
Esra Aydın, Ç. Öztürk, Oğuzhan Okçu et al.· Medical Journal of Western B...· 0 citations
Real-world findings highlight the need for personalized treatment sequencing in HR+/HER2− MBC patients presenting with bone-only metastasis, and first-line use showed a trend toward longer PFS, while later-line use showed a numerical trend toward longer OS.
S. Yıldırım, Büşra Bülbül, Bekir Ucun et al.· Cancers· 0 citations
Background Real-world data analyses show durable benefits with elacestrant, with or without prior treatment with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). This cohort focused on patients with ER-positive/HER2-negative estrogen receptor 1 (ESR1)-mutated metastatic breast cancer (mBC) treated with elacestrant afte...
G. Curigliano, M. de Laurentiis, N. Harbeck et al.· ESMO Open· 0 citations
Landmark-based conditional survival analysis provides clinically meaningful, time-updated prognostic information in HR+/HER2- mBC treated with first-line CDK4/6 inhibitors and support the integration of milestone-based conditional survival estimates alongside conventional baseline survival metrics in the CDK4/6i era.
IntroductionThe long-term survival impact of adding CDK4/6 inhibitors to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer remains a subject of active evaluation. We performed an updated meta-analysis incorporating the mature efficacy and survival data to comprehens...
W. Ben Kridis, A. Khanfir· Journal of Oncology Pharmacy...· 0 citations
Objective This study aimed to characterize the tumor response rate, progression-free survival (PFS), and overall survival (OS) among patients with HR-positive, HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors plus endocrine therapy at Ho Chi Minh City Oncology Hospital. Secondary objectives included i...
Thị Phan, Hoang Quy Nguyen· Frontiers in Oncology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.